Stockreport

Edgewise Therapeutics Announces Positive Two-Year Topline Results from the ARCH Open Label Trial of Sevasemten (EDG-5506) in Adults with Becker Muscular Dystrophy (Becker)

Edgewise Therapeutics, Inc.  (EWTX) 
PDF – The North Star Ambulatory Assessment (NSAA) remained stable relative to declines reported in Becker natural history studies –– Significant decreases were observed in c [Read more]